Clinical Trials
4 trialsNCT07612007 2026-06-01
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
Mayo Clinic
Phase 2 Not yet recruiting
NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
NCT04840186 2024-11-12
EXCALIBUR3
Oslo University Hospital
Phase 2 Suspended
NCT00153998 2009-02-27
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Technische Universität Dresden
Phase 2 Completed